开云app官网登录入口网页版-官方正版

[GetPortalCommentsPageByObjectIdResponse(id=2212828, encodeId=486522128283b, content=awaiting ae final processing，亲身体验，是秒据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Tue Jul 02 16:44:04 CST 2024, time=2024-07-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2209645, encodeId=e228220964519, content=投稿第二天，Awaiting AE Final Processing，来爬楼，看到对于这个问题，有问无答为主，是否等于拒稿？如果差不多就是拒稿了，能不能直接直接给reject，来这么一下不痛快的何苦来, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=37962243438, createdName=1214bfbbm26(暂无昵称), createdTime=Thu Jun 13 10:54:29 CST 2024, time=2024-06-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2214187, encodeId=6811221418ee7, content=投稿第二天，Awaiting AE Final Processing, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd7f4731790, createdName=bianyueyan, createdTime=Wed Jul 10 09:15:34 CST 2024, time=2024-07-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1234286, encodeId=d9b3123428608, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：转化医学;心血管 经验分享：2月11日提交的 3月15日外审结束给了大修 4月14日返修之后4月17日给的接收杂志效率很高，主编非常nice，版面费3000美金比较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff425709648, createdName=ms4000001964182854, createdTime=Sat Jul 23 19:22:09 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192927, encodeId=cc8f219292e60, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：12.18投稿 1.9号一审结束，审稿人态度良好，给的意见也比较温和，需要大修 2.29号修回 3.1 awaiting reviewer score 3.10 awaiting eic decision 现在一直没消息！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca8184855, createdName=ms6000000187674201, createdTime=Wed Mar 13 10:43:00 CST 2024, time=2024-03-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2195631, encodeId=d33f2195631a6, content=影响因子和aging cell 一样，nature aging拒了后来这的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Wed Mar 27 11:14:02 CST 2024, time=2024-03-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2187382, encodeId=fe96218e38223, content=偏重的研究方向：脑血管病 经验分享：请问这个杂志是水刊吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=08f22302355, createdName=Trr, createdTime=Thu Feb 15 10:39:17 CST 2024, time=2024-02-15, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2184662, encodeId=4b2b2184662a6, content=等待, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c77d5494646, createdName=ms7000000657762546, createdTime=Mon Jan 29 16:45:47 CST 2024, time=2024-01-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183667, encodeId=2033218366e2e, content=123, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4f48543542, createdName=ms5000000381647453, createdTime=Wed Jan 24 13:17:17 CST 2024, time=2024-01-24, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1212566, encodeId=91ff121256625, content=投稿第二天awaiting AE final processing,要哭了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12c68124177, createdName=ms4000000135134794, createdTime=Tue Apr 19 15:56:10 CST 2022, time=2022-04-19, status=1, ipAttribution=)]

2024-07-02 osmataku 来自北京

awaiting ae final processing，亲身体验，是秒据

63 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2212828, encodeId=486522128283b, content=awaiting ae final processing，亲身体验，是秒据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Tue Jul 02 16:44:04 CST 2024, time=2024-07-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2209645, encodeId=e228220964519, content=投稿第二天，Awaiting AE Final Processing，来爬楼，看到对于这个问题，有问无答为主，是否等于拒稿？如果差不多就是拒稿了，能不能直接直接给reject，来这么一下不痛快的何苦来, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=37962243438, createdName=1214bfbbm26(暂无昵称), createdTime=Thu Jun 13 10:54:29 CST 2024, time=2024-06-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2214187, encodeId=6811221418ee7, content=投稿第二天，Awaiting AE Final Processing, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd7f4731790, createdName=bianyueyan, createdTime=Wed Jul 10 09:15:34 CST 2024, time=2024-07-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1234286, encodeId=d9b3123428608, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：转化医学;心血管 经验分享：2月11日提交的 3月15日外审结束给了大修 4月14日返修之后4月17日给的接收杂志效率很高，主编非常nice，版面费3000美金比较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff425709648, createdName=ms4000001964182854, createdTime=Sat Jul 23 19:22:09 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192927, encodeId=cc8f219292e60, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：12.18投稿 1.9号一审结束，审稿人态度良好，给的意见也比较温和，需要大修 2.29号修回 3.1 awaiting reviewer score 3.10 awaiting eic decision 现在一直没消息！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca8184855, createdName=ms6000000187674201, createdTime=Wed Mar 13 10:43:00 CST 2024, time=2024-03-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2195631, encodeId=d33f2195631a6, content=影响因子和aging cell 一样，nature aging拒了后来这的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Wed Mar 27 11:14:02 CST 2024, time=2024-03-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2187382, encodeId=fe96218e38223, content=偏重的研究方向：脑血管病 经验分享：请问这个杂志是水刊吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=08f22302355, createdName=Trr, createdTime=Thu Feb 15 10:39:17 CST 2024, time=2024-02-15, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2184662, encodeId=4b2b2184662a6, content=等待, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c77d5494646, createdName=ms7000000657762546, createdTime=Mon Jan 29 16:45:47 CST 2024, time=2024-01-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183667, encodeId=2033218366e2e, content=123, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4f48543542, createdName=ms5000000381647453, createdTime=Wed Jan 24 13:17:17 CST 2024, time=2024-01-24, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1212566, encodeId=91ff121256625, content=投稿第二天awaiting AE final processing,要哭了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12c68124177, createdName=ms4000000135134794, createdTime=Tue Apr 19 15:56:10 CST 2022, time=2022-04-19, status=1, ipAttribution=)]

2024-06-13 1214bfbbm26(暂无昵称) 来自北京

投稿第二天，Awaiting AE Final Processing，来爬楼，看到对于这个问题，有问无答为主，是否等于拒稿？如果差不多就是拒稿了，能不能直接直接给reject，来这么一下不痛快的何苦来

62 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2212828, encodeId=486522128283b, content=awaiting ae final processing，亲身体验，是秒据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Tue Jul 02 16:44:04 CST 2024, time=2024-07-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2209645, encodeId=e228220964519, content=投稿第二天，Awaiting AE Final Processing，来爬楼，看到对于这个问题，有问无答为主，是否等于拒稿？如果差不多就是拒稿了，能不能直接直接给reject，来这么一下不痛快的何苦来, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=37962243438, createdName=1214bfbbm26(暂无昵称), createdTime=Thu Jun 13 10:54:29 CST 2024, time=2024-06-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2214187, encodeId=6811221418ee7, content=投稿第二天，Awaiting AE Final Processing, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd7f4731790, createdName=bianyueyan, createdTime=Wed Jul 10 09:15:34 CST 2024, time=2024-07-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1234286, encodeId=d9b3123428608, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：转化医学;心血管 经验分享：2月11日提交的 3月15日外审结束给了大修 4月14日返修之后4月17日给的接收杂志效率很高，主编非常nice，版面费3000美金比较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff425709648, createdName=ms4000001964182854, createdTime=Sat Jul 23 19:22:09 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192927, encodeId=cc8f219292e60, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：12.18投稿 1.9号一审结束，审稿人态度良好，给的意见也比较温和，需要大修 2.29号修回 3.1 awaiting reviewer score 3.10 awaiting eic decision 现在一直没消息！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca8184855, createdName=ms6000000187674201, createdTime=Wed Mar 13 10:43:00 CST 2024, time=2024-03-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2195631, encodeId=d33f2195631a6, content=影响因子和aging cell 一样，nature aging拒了后来这的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Wed Mar 27 11:14:02 CST 2024, time=2024-03-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2187382, encodeId=fe96218e38223, content=偏重的研究方向：脑血管病 经验分享：请问这个杂志是水刊吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=08f22302355, createdName=Trr, createdTime=Thu Feb 15 10:39:17 CST 2024, time=2024-02-15, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2184662, encodeId=4b2b2184662a6, content=等待, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c77d5494646, createdName=ms7000000657762546, createdTime=Mon Jan 29 16:45:47 CST 2024, time=2024-01-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183667, encodeId=2033218366e2e, content=123, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4f48543542, createdName=ms5000000381647453, createdTime=Wed Jan 24 13:17:17 CST 2024, time=2024-01-24, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1212566, encodeId=91ff121256625, content=投稿第二天awaiting AE final processing,要哭了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12c68124177, createdName=ms4000000135134794, createdTime=Tue Apr 19 15:56:10 CST 2022, time=2022-04-19, status=1, ipAttribution=)]

2024-07-10 bianyueyan 来自北京

投稿第二天，Awaiting AE Final Processing

52 0

[GetPortalCommentsPageByObjectIdResponse(id=2212828, encodeId=486522128283b, content=awaiting ae final processing，亲身体验，是秒据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Tue Jul 02 16:44:04 CST 2024, time=2024-07-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2209645, encodeId=e228220964519, content=投稿第二天，Awaiting AE Final Processing，来爬楼，看到对于这个问题，有问无答为主，是否等于拒稿？如果差不多就是拒稿了，能不能直接直接给reject，来这么一下不痛快的何苦来, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=37962243438, createdName=1214bfbbm26(暂无昵称), createdTime=Thu Jun 13 10:54:29 CST 2024, time=2024-06-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2214187, encodeId=6811221418ee7, content=投稿第二天，Awaiting AE Final Processing, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd7f4731790, createdName=bianyueyan, createdTime=Wed Jul 10 09:15:34 CST 2024, time=2024-07-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1234286, encodeId=d9b3123428608, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：转化医学;心血管 经验分享：2月11日提交的 3月15日外审结束给了大修 4月14日返修之后4月17日给的接收杂志效率很高，主编非常nice，版面费3000美金比较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff425709648, createdName=ms4000001964182854, createdTime=Sat Jul 23 19:22:09 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192927, encodeId=cc8f219292e60, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：12.18投稿 1.9号一审结束，审稿人态度良好，给的意见也比较温和，需要大修 2.29号修回 3.1 awaiting reviewer score 3.10 awaiting eic decision 现在一直没消息！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca8184855, createdName=ms6000000187674201, createdTime=Wed Mar 13 10:43:00 CST 2024, time=2024-03-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2195631, encodeId=d33f2195631a6, content=影响因子和aging cell 一样，nature aging拒了后来这的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Wed Mar 27 11:14:02 CST 2024, time=2024-03-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2187382, encodeId=fe96218e38223, content=偏重的研究方向：脑血管病 经验分享：请问这个杂志是水刊吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=08f22302355, createdName=Trr, createdTime=Thu Feb 15 10:39:17 CST 2024, time=2024-02-15, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2184662, encodeId=4b2b2184662a6, content=等待, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c77d5494646, createdName=ms7000000657762546, createdTime=Mon Jan 29 16:45:47 CST 2024, time=2024-01-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183667, encodeId=2033218366e2e, content=123, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4f48543542, createdName=ms5000000381647453, createdTime=Wed Jan 24 13:17:17 CST 2024, time=2024-01-24, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1212566, encodeId=91ff121256625, content=投稿第二天awaiting AE final processing,要哭了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12c68124177, createdName=ms4000000135134794, createdTime=Tue Apr 19 15:56:10 CST 2022, time=2022-04-19, status=1, ipAttribution=)]

2022-07-23 ms4000001964182854

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：转化医学;心血管
经验分享：2月11日提交的 3月15日外审结束给了大修 4月14日返修之后4月17日给的接收杂志效率很高，主编非常nice，版面费3000美金比较高

144 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2212828, encodeId=486522128283b, content=awaiting ae final processing，亲身体验，是秒据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Tue Jul 02 16:44:04 CST 2024, time=2024-07-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2209645, encodeId=e228220964519, content=投稿第二天，Awaiting AE Final Processing，来爬楼，看到对于这个问题，有问无答为主，是否等于拒稿？如果差不多就是拒稿了，能不能直接直接给reject，来这么一下不痛快的何苦来, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=37962243438, createdName=1214bfbbm26(暂无昵称), createdTime=Thu Jun 13 10:54:29 CST 2024, time=2024-06-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2214187, encodeId=6811221418ee7, content=投稿第二天，Awaiting AE Final Processing, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd7f4731790, createdName=bianyueyan, createdTime=Wed Jul 10 09:15:34 CST 2024, time=2024-07-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1234286, encodeId=d9b3123428608, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：转化医学;心血管 经验分享：2月11日提交的 3月15日外审结束给了大修 4月14日返修之后4月17日给的接收杂志效率很高，主编非常nice，版面费3000美金比较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff425709648, createdName=ms4000001964182854, createdTime=Sat Jul 23 19:22:09 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192927, encodeId=cc8f219292e60, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：12.18投稿 1.9号一审结束，审稿人态度良好，给的意见也比较温和，需要大修 2.29号修回 3.1 awaiting reviewer score 3.10 awaiting eic decision 现在一直没消息！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca8184855, createdName=ms6000000187674201, createdTime=Wed Mar 13 10:43:00 CST 2024, time=2024-03-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2195631, encodeId=d33f2195631a6, content=影响因子和aging cell 一样，nature aging拒了后来这的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Wed Mar 27 11:14:02 CST 2024, time=2024-03-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2187382, encodeId=fe96218e38223, content=偏重的研究方向：脑血管病 经验分享：请问这个杂志是水刊吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=08f22302355, createdName=Trr, createdTime=Thu Feb 15 10:39:17 CST 2024, time=2024-02-15, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2184662, encodeId=4b2b2184662a6, content=等待, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c77d5494646, createdName=ms7000000657762546, createdTime=Mon Jan 29 16:45:47 CST 2024, time=2024-01-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183667, encodeId=2033218366e2e, content=123, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4f48543542, createdName=ms5000000381647453, createdTime=Wed Jan 24 13:17:17 CST 2024, time=2024-01-24, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1212566, encodeId=91ff121256625, content=投稿第二天awaiting AE final processing,要哭了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12c68124177, createdName=ms4000000135134794, createdTime=Tue Apr 19 15:56:10 CST 2022, time=2022-04-19, status=1, ipAttribution=)]

2024-03-13 ms6000000187674201 来自上海

审稿速度:1.0 | 投稿命中率:25.0
经验分享：12.18投稿 1.9号一审结束，审稿人态度良好，给的意见也比较温和，需要大修 2.29号修回 3.1 awaiting reviewer score 3.10 awaiting eic decision 现在一直没消息！

76 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2212828, encodeId=486522128283b, content=awaiting ae final processing，亲身体验，是秒据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Tue Jul 02 16:44:04 CST 2024, time=2024-07-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2209645, encodeId=e228220964519, content=投稿第二天，Awaiting AE Final Processing，来爬楼，看到对于这个问题，有问无答为主，是否等于拒稿？如果差不多就是拒稿了，能不能直接直接给reject，来这么一下不痛快的何苦来, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=37962243438, createdName=1214bfbbm26(暂无昵称), createdTime=Thu Jun 13 10:54:29 CST 2024, time=2024-06-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2214187, encodeId=6811221418ee7, content=投稿第二天，Awaiting AE Final Processing, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd7f4731790, createdName=bianyueyan, createdTime=Wed Jul 10 09:15:34 CST 2024, time=2024-07-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1234286, encodeId=d9b3123428608, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：转化医学;心血管 经验分享：2月11日提交的 3月15日外审结束给了大修 4月14日返修之后4月17日给的接收杂志效率很高，主编非常nice，版面费3000美金比较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff425709648, createdName=ms4000001964182854, createdTime=Sat Jul 23 19:22:09 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192927, encodeId=cc8f219292e60, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：12.18投稿 1.9号一审结束，审稿人态度良好，给的意见也比较温和，需要大修 2.29号修回 3.1 awaiting reviewer score 3.10 awaiting eic decision 现在一直没消息！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca8184855, createdName=ms6000000187674201, createdTime=Wed Mar 13 10:43:00 CST 2024, time=2024-03-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2195631, encodeId=d33f2195631a6, content=影响因子和aging cell 一样，nature aging拒了后来这的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Wed Mar 27 11:14:02 CST 2024, time=2024-03-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2187382, encodeId=fe96218e38223, content=偏重的研究方向：脑血管病 经验分享：请问这个杂志是水刊吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=08f22302355, createdName=Trr, createdTime=Thu Feb 15 10:39:17 CST 2024, time=2024-02-15, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2184662, encodeId=4b2b2184662a6, content=等待, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c77d5494646, createdName=ms7000000657762546, createdTime=Mon Jan 29 16:45:47 CST 2024, time=2024-01-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183667, encodeId=2033218366e2e, content=123, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4f48543542, createdName=ms5000000381647453, createdTime=Wed Jan 24 13:17:17 CST 2024, time=2024-01-24, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1212566, encodeId=91ff121256625, content=投稿第二天awaiting AE final processing,要哭了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12c68124177, createdName=ms4000000135134794, createdTime=Tue Apr 19 15:56:10 CST 2022, time=2022-04-19, status=1, ipAttribution=)]

2024-03-27 osmataku 来自北京

影响因子和aging cell 一样，nature aging拒了后来这的

91 0

[GetPortalCommentsPageByObjectIdResponse(id=2212828, encodeId=486522128283b, content=awaiting ae final processing，亲身体验，是秒据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Tue Jul 02 16:44:04 CST 2024, time=2024-07-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2209645, encodeId=e228220964519, content=投稿第二天，Awaiting AE Final Processing，来爬楼，看到对于这个问题，有问无答为主，是否等于拒稿？如果差不多就是拒稿了，能不能直接直接给reject，来这么一下不痛快的何苦来, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=37962243438, createdName=1214bfbbm26(暂无昵称), createdTime=Thu Jun 13 10:54:29 CST 2024, time=2024-06-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2214187, encodeId=6811221418ee7, content=投稿第二天，Awaiting AE Final Processing, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd7f4731790, createdName=bianyueyan, createdTime=Wed Jul 10 09:15:34 CST 2024, time=2024-07-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1234286, encodeId=d9b3123428608, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：转化医学;心血管 经验分享：2月11日提交的 3月15日外审结束给了大修 4月14日返修之后4月17日给的接收杂志效率很高，主编非常nice，版面费3000美金比较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff425709648, createdName=ms4000001964182854, createdTime=Sat Jul 23 19:22:09 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192927, encodeId=cc8f219292e60, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：12.18投稿 1.9号一审结束，审稿人态度良好，给的意见也比较温和，需要大修 2.29号修回 3.1 awaiting reviewer score 3.10 awaiting eic decision 现在一直没消息！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca8184855, createdName=ms6000000187674201, createdTime=Wed Mar 13 10:43:00 CST 2024, time=2024-03-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2195631, encodeId=d33f2195631a6, content=影响因子和aging cell 一样，nature aging拒了后来这的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Wed Mar 27 11:14:02 CST 2024, time=2024-03-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2187382, encodeId=fe96218e38223, content=偏重的研究方向：脑血管病 经验分享：请问这个杂志是水刊吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=08f22302355, createdName=Trr, createdTime=Thu Feb 15 10:39:17 CST 2024, time=2024-02-15, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2184662, encodeId=4b2b2184662a6, content=等待, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c77d5494646, createdName=ms7000000657762546, createdTime=Mon Jan 29 16:45:47 CST 2024, time=2024-01-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183667, encodeId=2033218366e2e, content=123, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4f48543542, createdName=ms5000000381647453, createdTime=Wed Jan 24 13:17:17 CST 2024, time=2024-01-24, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1212566, encodeId=91ff121256625, content=投稿第二天awaiting AE final processing,要哭了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12c68124177, createdName=ms4000000135134794, createdTime=Tue Apr 19 15:56:10 CST 2022, time=2022-04-19, status=1, ipAttribution=)]

2024-02-15 Trr 来自安徽省

偏重的研究方向：脑血管病
经验分享：请问这个杂志是水刊吗？

79 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2212828, encodeId=486522128283b, content=awaiting ae final processing，亲身体验，是秒据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Tue Jul 02 16:44:04 CST 2024, time=2024-07-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2209645, encodeId=e228220964519, content=投稿第二天，Awaiting AE Final Processing，来爬楼，看到对于这个问题，有问无答为主，是否等于拒稿？如果差不多就是拒稿了，能不能直接直接给reject，来这么一下不痛快的何苦来, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=37962243438, createdName=1214bfbbm26(暂无昵称), createdTime=Thu Jun 13 10:54:29 CST 2024, time=2024-06-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2214187, encodeId=6811221418ee7, content=投稿第二天，Awaiting AE Final Processing, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd7f4731790, createdName=bianyueyan, createdTime=Wed Jul 10 09:15:34 CST 2024, time=2024-07-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1234286, encodeId=d9b3123428608, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：转化医学;心血管 经验分享：2月11日提交的 3月15日外审结束给了大修 4月14日返修之后4月17日给的接收杂志效率很高，主编非常nice，版面费3000美金比较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff425709648, createdName=ms4000001964182854, createdTime=Sat Jul 23 19:22:09 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192927, encodeId=cc8f219292e60, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：12.18投稿 1.9号一审结束，审稿人态度良好，给的意见也比较温和，需要大修 2.29号修回 3.1 awaiting reviewer score 3.10 awaiting eic decision 现在一直没消息！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca8184855, createdName=ms6000000187674201, createdTime=Wed Mar 13 10:43:00 CST 2024, time=2024-03-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2195631, encodeId=d33f2195631a6, content=影响因子和aging cell 一样，nature aging拒了后来这的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Wed Mar 27 11:14:02 CST 2024, time=2024-03-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2187382, encodeId=fe96218e38223, content=偏重的研究方向：脑血管病 经验分享：请问这个杂志是水刊吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=08f22302355, createdName=Trr, createdTime=Thu Feb 15 10:39:17 CST 2024, time=2024-02-15, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2184662, encodeId=4b2b2184662a6, content=等待, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c77d5494646, createdName=ms7000000657762546, createdTime=Mon Jan 29 16:45:47 CST 2024, time=2024-01-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183667, encodeId=2033218366e2e, content=123, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4f48543542, createdName=ms5000000381647453, createdTime=Wed Jan 24 13:17:17 CST 2024, time=2024-01-24, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1212566, encodeId=91ff121256625, content=投稿第二天awaiting AE final processing,要哭了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12c68124177, createdName=ms4000000135134794, createdTime=Tue Apr 19 15:56:10 CST 2022, time=2022-04-19, status=1, ipAttribution=)]

2024-01-29 ms7000000657762546 来自北京

等待

78 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2212828, encodeId=486522128283b, content=awaiting ae final processing，亲身体验，是秒据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Tue Jul 02 16:44:04 CST 2024, time=2024-07-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2209645, encodeId=e228220964519, content=投稿第二天，Awaiting AE Final Processing，来爬楼，看到对于这个问题，有问无答为主，是否等于拒稿？如果差不多就是拒稿了，能不能直接直接给reject，来这么一下不痛快的何苦来, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=37962243438, createdName=1214bfbbm26(暂无昵称), createdTime=Thu Jun 13 10:54:29 CST 2024, time=2024-06-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2214187, encodeId=6811221418ee7, content=投稿第二天，Awaiting AE Final Processing, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd7f4731790, createdName=bianyueyan, createdTime=Wed Jul 10 09:15:34 CST 2024, time=2024-07-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1234286, encodeId=d9b3123428608, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：转化医学;心血管 经验分享：2月11日提交的 3月15日外审结束给了大修 4月14日返修之后4月17日给的接收杂志效率很高，主编非常nice，版面费3000美金比较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff425709648, createdName=ms4000001964182854, createdTime=Sat Jul 23 19:22:09 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192927, encodeId=cc8f219292e60, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：12.18投稿 1.9号一审结束，审稿人态度良好，给的意见也比较温和，需要大修 2.29号修回 3.1 awaiting reviewer score 3.10 awaiting eic decision 现在一直没消息！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca8184855, createdName=ms6000000187674201, createdTime=Wed Mar 13 10:43:00 CST 2024, time=2024-03-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2195631, encodeId=d33f2195631a6, content=影响因子和aging cell 一样，nature aging拒了后来这的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Wed Mar 27 11:14:02 CST 2024, time=2024-03-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2187382, encodeId=fe96218e38223, content=偏重的研究方向：脑血管病 经验分享：请问这个杂志是水刊吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=08f22302355, createdName=Trr, createdTime=Thu Feb 15 10:39:17 CST 2024, time=2024-02-15, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2184662, encodeId=4b2b2184662a6, content=等待, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c77d5494646, createdName=ms7000000657762546, createdTime=Mon Jan 29 16:45:47 CST 2024, time=2024-01-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183667, encodeId=2033218366e2e, content=123, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4f48543542, createdName=ms5000000381647453, createdTime=Wed Jan 24 13:17:17 CST 2024, time=2024-01-24, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1212566, encodeId=91ff121256625, content=投稿第二天awaiting AE final processing,要哭了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12c68124177, createdName=ms4000000135134794, createdTime=Tue Apr 19 15:56:10 CST 2022, time=2022-04-19, status=1, ipAttribution=)]

2024-01-24 ms5000000381647453 来自四川省

123

86 0

[GetPortalCommentsPageByObjectIdResponse(id=2212828, encodeId=486522128283b, content=awaiting ae final processing，亲身体验，是秒据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Tue Jul 02 16:44:04 CST 2024, time=2024-07-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2209645, encodeId=e228220964519, content=投稿第二天，Awaiting AE Final Processing，来爬楼，看到对于这个问题，有问无答为主，是否等于拒稿？如果差不多就是拒稿了，能不能直接直接给reject，来这么一下不痛快的何苦来, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=37962243438, createdName=1214bfbbm26(暂无昵称), createdTime=Thu Jun 13 10:54:29 CST 2024, time=2024-06-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2214187, encodeId=6811221418ee7, content=投稿第二天，Awaiting AE Final Processing, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd7f4731790, createdName=bianyueyan, createdTime=Wed Jul 10 09:15:34 CST 2024, time=2024-07-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1234286, encodeId=d9b3123428608, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：转化医学;心血管 经验分享：2月11日提交的 3月15日外审结束给了大修 4月14日返修之后4月17日给的接收杂志效率很高，主编非常nice，版面费3000美金比较高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff425709648, createdName=ms4000001964182854, createdTime=Sat Jul 23 19:22:09 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192927, encodeId=cc8f219292e60, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：12.18投稿 1.9号一审结束，审稿人态度良好，给的意见也比较温和，需要大修 2.29号修回 3.1 awaiting reviewer score 3.10 awaiting eic decision 现在一直没消息！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca8184855, createdName=ms6000000187674201, createdTime=Wed Mar 13 10:43:00 CST 2024, time=2024-03-13, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2195631, encodeId=d33f2195631a6, content=影响因子和aging cell 一样，nature aging拒了后来这的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a82b5450835, createdName=osmataku, createdTime=Wed Mar 27 11:14:02 CST 2024, time=2024-03-27, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2187382, encodeId=fe96218e38223, content=偏重的研究方向：脑血管病 经验分享：请问这个杂志是水刊吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=08f22302355, createdName=Trr, createdTime=Thu Feb 15 10:39:17 CST 2024, time=2024-02-15, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2184662, encodeId=4b2b2184662a6, content=等待, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c77d5494646, createdName=ms7000000657762546, createdTime=Mon Jan 29 16:45:47 CST 2024, time=2024-01-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2183667, encodeId=2033218366e2e, content=123, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4f48543542, createdName=ms5000000381647453, createdTime=Wed Jan 24 13:17:17 CST 2024, time=2024-01-24, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1212566, encodeId=91ff121256625, content=投稿第二天awaiting AE final processing,要哭了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12c68124177, createdName=ms4000000135134794, createdTime=Tue Apr 19 15:56:10 CST 2022, time=2022-04-19, status=1, ipAttribution=)]

2022-04-19 ms4000000135134794

投稿第二天awaiting AE final processing,要哭了

140 10

展开10条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务